RebiSmart™

  • Post author:
  • Post published:9. August 2012
  • Post category:Uncategorized
  • Post comments:0 Comments

/AdminMerckSerono har udviklet en elektronisk autoinjekter, der gør det muligt at holde øje med, hvornår man har taget den sidste injektion og som desuden kan være til hjælp for scleroseramte,…

Continue ReadingRebiSmart™

Pressemeddelelse

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif® (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab improved from baseline, whereas the mean disability of those on Rebif worsened. The treatment benefits of alemtuzumab were sustained for at least three years, even though the majority of alemtuzumab-treated patients were last dosed two years earlier. These results come from the final three-year analysis of a Phase 2 clinical study (CAMMS223) reported in the Oct. 23 issue of the New England Journal of Medicine. The study involved 334 patients who had not previously been treated for their disease.

(more…)

Continue ReadingPressemeddelelse

Sclerose.info er meget glade for igen at kunne inviterer dig til foredrag med tidl. verdensmester Arne Nielsson

  • Post author:
  • Post published:13. April 2012
  • Post category:Uncategorized
  • Post comments:0 Comments

Hvordan motiverer man sig til at tænke positivt og være i mulighedernes verden på trods af svære livsbetingelser?Arne Nielsson har nogle fantastiske og inspirerende bud på dette!FOREDRAG OG PATIENTMØDEDen tidligere…

Continue ReadingSclerose.info er meget glade for igen at kunne inviterer dig til foredrag med tidl. verdensmester Arne Nielsson